These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vaccines under development: group B streptococcus, herpes-zoster, HIV, malaria and dengue. da Silva LJ; Richtmann R J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S115-24. PubMed ID: 16721441 [TBL] [Abstract][Full Text] [Related]
5. Infectious disease: Beating the big three. Bourzac K Nature; 2014 Mar; 507(7490):S4-7. PubMed ID: 24611168 [No Abstract] [Full Text] [Related]
6. Combined efforts in immunology and vaccinology will lead to effective vaccines against HIV, tuberculosis and malaria. Chiodi F; Kaufmann SH J Intern Med; 2014 May; 275(5):442-3. PubMed ID: 24635534 [No Abstract] [Full Text] [Related]
7. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa. Mamotte N; Wassenaar D; Koen J; Essack Z BMC Med Ethics; 2010 Mar; 11():3. PubMed ID: 20211030 [TBL] [Abstract][Full Text] [Related]
8. Progress toward an HIV vaccine. Letvin NL Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510 [TBL] [Abstract][Full Text] [Related]
9. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
10. Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation. Afolabi MO; Adetifa JU; Imoukhuede EB; Viebig NK; Kampmann B; Bojang K Am J Trop Med Hyg; 2014 May; 90(5):908-14. PubMed ID: 24615122 [TBL] [Abstract][Full Text] [Related]
11. [Betting on the International AIDS Vaccine Initiative: an anti-AIDS vaccine in 10 years]. Manus JM Rev Infirm; 1999 Oct; (53):11. PubMed ID: 10797793 [No Abstract] [Full Text] [Related]
12. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned. Kilpeläinen A; Maya-Hoyos M; Saubí N; Soto CY; Joseph Munne J Expert Rev Vaccines; 2018 Nov; 17(11):1005-1020. PubMed ID: 30300040 [TBL] [Abstract][Full Text] [Related]
13. Accelerating next-generation vaccine development for global disease prevention. Koff WC; Burton DR; Johnson PR; Walker BD; King CR; Nabel GJ; Ahmed R; Bhan MK; Plotkin SA Science; 2013 May; 340(6136):1232910. PubMed ID: 23723240 [TBL] [Abstract][Full Text] [Related]
14. Research priorities for vaccines to be used at a global level. Lambert PH Behring Inst Mitt; 1994 Dec; (95):1-6. PubMed ID: 7755502 [TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
16. [HIV/AIDS, tuberculosis and malaria can now be effectively combated]. Nordström A; Dybul M Lakartidningen; 2013 Apr 3-16; 110(27-28):1275. PubMed ID: 23951879 [No Abstract] [Full Text] [Related]
17. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Matarazzo L; Bettencourt PJG Front Immunol; 2023; 14():1172691. PubMed ID: 37168860 [TBL] [Abstract][Full Text] [Related]
18. A road map to control malaria, tuberculosis, and human immunodeficiency virus/AIDS. Frieden TR; Teklehaimanot A; Chideya S; Farmer P; Kim JY; Raviglione MC Arch Intern Med; 2009 Oct; 169(18):1650-2. PubMed ID: 19822819 [No Abstract] [Full Text] [Related]
20. Global fund for AIDS, tuberculosis and malaria. Nordstrom A Lancet; 2002 May; 359(9317):1621-2. PubMed ID: 12048001 [No Abstract] [Full Text] [Related] [Next] [New Search]